Scarica l'app Stockscreener
491.47
5.69%
26.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$465.02
Aprire:
$471.645
Volume 24 ore:
2.92M
Relative Volume:
2.02
Capitalizzazione di mercato:
$124.70B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
34.64
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+2.84%
1M Prestazione:
+8.09%
6M Prestazione:
+24.13%
1 anno Prestazione:
+6.25%
Intervallo 1D:
$471.64
$503.88
Intervallo di 1 settimana:
$454.40
$503.88
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Ins - GuruFocus
Vertex veers upwards on impressive results - The Pharma Letter
Vertex Pharmaceuticals Signals Confident Growth Beyond CF - TipRanks
Vertex’s CRISPR therapy rebounds in latest earnings - BioPharma Dive
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase - Finviz
Vertex Pharmaceuticals (VRTX): Scotiabank Raises Price Target to $558 | VRTX Stock News - GuruFocus
RBC Capital Lowers Vertex Pharmaceuticals' (VRTX) Price Target | - GuruFocus
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Vertex Pharmaceuticals (VRTX) Analyst Maintains Rating and Raises Price Target | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says - marketscreener.com
Top Biotech Stocks To ConsiderFebruary 13th - MarketBeat
Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year - Fierce Pharma
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Topline Grows 10% - FXDailyReport.Com
Vertex Prepares Povetacicept For APRIL/BAFF Battle - Citeline News & Insights
Agree To Purchase Vertex Pharmaceuticals At $320, Earn 4.4% Using Options - Nasdaq
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp - BioSpace
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News - GuruFocus
Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Insider Monkey
AI for investors - MLQ.ai
Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating - marketscreener.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Outperform" at Oppenheimer - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Vertex Pharma Q4 2025 Earnings Results - AlphaStreet News
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts - BioSpace
Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga
11,989 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by ING Groep NV - MarketBeat
Atria Investments Inc Acquires 2,418 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highligh - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Drops After Hours — Here's Why It's Trending Tonight - Benzinga
Vertex Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Vertex Pharmaceuticals (VRTX) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Vertex Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 2,021 Shares - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,751 Shares of Stock - MarketBeat
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 466 Shares of Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Reports Mixed Q4 Results with Stro - GuruFocus
How Vertex Pharmaceuticals Incorporated stock responds to policy changesOptions Play & Daily Stock Momentum Reports - mfd.ru
VRTX: 2025 delivered robust growth and diversification, with 2026 set for further expansion and innovation - TradingView
Earnings call transcript: Vertex Q4 2025 sees revenue growth, EPS miss - Investing.com
Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Sells $633,551.68 in Stock - MarketBeat
Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Revenue Expectations - GuruFocus
Vertex Pharma Q4 revenue rises 10% YoY, but earnings miss analyst expectations - Investing.com Australia
Vertex Q4 results miss on bottom line; 2026 revenue guidance in-line - Seeking Alpha
Vertex Pharmaceuticals falls after Q4 profit miss - TradingView
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.49%
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):